Video Experimental Relacionado
Updated: Jun 30, 2026
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
La adiponectina y la protección contra la diabetes mellitus tipo 2
Joachim Spranger1, Anja Kroke, Matthias Möhlig
1Department of Nutrition, Endocrinology, and Metabolism, Benjamin Franklin Medical Centre, Free University Berlin, Germany. spranger@mail.dife.de
Lancet (London, England)
|January 28, 2003
Resumen
Los niveles más bajos de adiponectina, una hormona peptídica, están relacionados con un mayor riesgo de desarrollar diabetes tipo 2. Las concentraciones más altas de adiponectina se asocian con un riesgo significativamente reducido de este trastorno metabólico.
Área de la Ciencia:
- Endocrinología Endocrinología.
- Enfermedades Metabólicas Las enfermedades metabólicas.
- La bioquímica es la bioquímica.
Sus antecedentes:
- La adiponectina es una hormona peptídica secretada por los adipocitos.
- Posee propiedades antiinflamatorias y sensibilizantes a la insulina.
- Su papel en el desarrollo de la diabetes tipo 2 requiere más investigación.
Objetivo del estudio:
- Investigar la asociación independiente entre las concentraciones basales de adiponectina en plasma y el riesgo de desarrollar diabetes tipo 2.
- Para determinar si los niveles de adiponectina pueden servir como un biomarcador predictivo para la diabetes tipo 2.
Principales métodos:
- Se empleó un diseño de estudio de casos y controles anidados.
- Las concentraciones basales de adiponectina en plasma se midieron en individuos aparentemente sanos.
- Se realizaron análisis estadísticos, incluido el ajuste por múltiples factores de confusión.
Principales resultados:
- Las personas que posteriormente desarrollaron diabetes tipo 2 tenían concentraciones plasmáticas de adiponectina basal significativamente más bajas en comparación con los controles (5.34 microg / ml frente a 6.87 microg / ml, p <0.0001).
- Las altas concentraciones de adiponectina (cuarto cuartil) se asociaron con un riesgo relativo sustancialmente reducido de diabetes tipo 2 (OR 0,3, IC del 95% 0,2-0,7) después del ajuste multivariable.
- Esta asociación se mantuvo significativa después de ajustar por edad, sexo, indicadores de obesidad, factores de estilo de vida y control glucémico.
Conclusiones:
- La concentración plasmática de adiponectina se asocia de forma independiente con un riesgo reducido de diabetes tipo 2 en individuos aparentemente sanos.
- La adiponectina puede desempeñar un papel protector en la patogénesis de la diabetes tipo 2.
- Estos hallazgos sugieren el potencial de la adiponectina como biomarcador para la evaluación del riesgo de diabetes tipo 2.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.